Product information and disease descriptionProduct description
Phase of product development
8 evidence topics · 9 sources
Regulatory status: Submission planned; BLA planned on the basis of the phase 3 CAPTIVATE trial, with Part B top-line results expected by the end of 2028
Launch
No evidence found.
Single pivotal phase 3 trial announced, November 2024
Phase 3 CAPTIVATE trial initiated, February 2025
Interim responder analysis: early GO decision, March 2026
Trial resizing and removal of the 600 mg arm from Part B
FDA written feedback on antinuclear antibody screening and drug-induced lupus, March 2026
Orphan drug, fast track, or breakthrough therapy designation for CIDP
No evidence found.